Between 6 and 9 April, the world of Multiple Myeloma research will convene for a virtual meeting involving haematologists and clinical trial experts from Europe and beyond.
This virtual congress is promoted by the European EMN network, headquartered in Rotterdam, with the support of the Italian team in Turin, and in collaboration with the ER Congressi agency.
New therapeutic approaches aimed at increasing survival and quality of life of myeloma patients will be addressed. Sponsored sessions will provide a valuable overview of the new molecules and innovative therapeutic approaches.
The third edition of the European Myeloma Network Conference will take place from Wednesday 6 to Saturday 9 April, and it will be streamed on the emn2022 platform. As a pan-European network of excellence, EMN aims to promote collaboration between research centres and study groups across the continent, and ultimately to obtain quicker, more effective results in the treatment of plasma cell neoplasms.
Registrations (via the compilation of the module available on the emn2022 website) are discounted for “early birds” applying before 31 March 2022. The scientific sessions will be recorded and available on the emn2022 platform until 30 June 2022.
Where applicable, and contingent on the category specified during registration (medics, nurses, biologists, data mangers, researchers etc.), participants will obtain CME (Continual Medical Education) and EBAH (European Board for Accreditation in Haematology) credits. The press area of the website also features media accreditation for those interested in participating.
The four days of meeting (scheduled for the most part in the afternoon to favour those operating within the sector and often working in outpatients) constitute an intense conference programme. They are complemented by lectures and sessions detailing new therapeutic approaches, and strategies aimed at enhancing survival and quality of life for patients affected by Multiple Myeloma.
Of particular significance are the sponsored symposia, focusing on the progress related to the use of innovative molecules in clinical trials. In addition, the eight best abstracts submitted to the conference will be presented in a dedicated Oral Abstract session of the meeting, and all the submitted works will be published in the scientific journal HemaSphere.
The program coordinators are Professors Pieter Sonneveld (Rotterdam), Sonja Zweegman and Niels van de Donk (Amsterdam), representing the Netherlands; whilst their colleagues Professors Mario Boccadoro, Francesca Gay and Doctor Roberto Mina (Turin) will represent Italy during this important event. The international nature of the event is further evidenced by the five European countries of the conference scientific board: besides the EMN president Pieter Sonneveld (the Netherlands), and the vice president Prof. Mario Boccadoro (Italy), we have internationally renowned experts, such as Prof. Hermann Einsele (Germany), Prof. Maria-Victoria Mateos (Spain) and Prof. Philippe Moreau (France). More numerous still - from Europe and beyond - are the countries represented by the various speakers and chairpersons. Their collaboration provides further confirmation of the reach and international nature of the event.